RSCM
NKTR icon

Rock Springs Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Rock Springs Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-4,333
Closed -$738K – 79
2013
Q4 		$738K Buy
+4,333
New +$699K 0.26% 67

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Rock Springs Capital Management's NKTR Position: Q1 2014 in Review

Rock Springs Capital Management sold out of Nektar Therapeutics (NKTR) in Q1 2014, closing a stake of 4,333 shares — an estimated $738K sold.

Rock Springs Capital Management first reported a position in NKTR in Q4 2013 and held it in 1 quarter. The position peaked at $738K in Q4 2013. 138 funds tracked by Wall St. Rank hold NKTR as of Q1 2014.

  • Rock Springs Capital Management reported no remaining Nektar Therapeutics position as of Q1 2014 after selling out during the quarter.
  • Rock Springs Capital Management sold 4,333 Nektar Therapeutics shares in Q1 2014, an estimated $738K.
  • Rock Springs Capital Management first reported a position in Nektar Therapeutics in Q4 2013 and held it in 1 quarter.
  • Rock Springs Capital Management's Nektar Therapeutics position peaked at $738K in Q4 2013.
  • 138 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2014.

Based on Rock Springs Capital Management's 13F filing for Q1 2014, filed 15 May 2014.